Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combined With CACAG Regimen vs BAT Regimen in Relapsed/Refractory Acute Myeloid Leukemia
NCT06084819Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2023
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Overall Response Rate at 1 month. Started Aug 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06084819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084819.